Celularity Company Insiders
| CELU Stock | USD 1.54 0.05 3.36% |
Celularity employs about 120 people. The company is managed by 17 executives with a total tenure of roughly 280 years, averaging almost 16.0 years of service per executive, having 7.06 employees per reported executive. Breaking down Celularity's management performance can provide insight into the firm performance.
Celularity |
Celularity Management Team Effectiveness
The company has return on total asset (ROA) of (0.1745) % which means that it has lost $0.1745 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.475) %, meaning that it created substantial loss on money invested by shareholders. Celularity's management efficiency ratios could be used to measure how well Celularity manages its routine affairs as well as how well it operates its assets and liabilities.Celularity Workforce Comparison
Celularity is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 227. Celularity totals roughly 120 in number of employees claiming about 53% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.73) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.24) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.24. Celularity Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Celularity insiders, such as employees or executives, is commonly permitted as long as it does not rely on Celularity's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Celularity insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Brigido Stephen over three weeks ago Disposition of 10000 shares by Brigido Stephen of Celularity subject to Rule 16b-3 | ||
John Haines over three weeks ago Disposition of 20000 shares by John Haines of Celularity subject to Rule 16b-3 | ||
Brigido Stephen over a month ago Acquisition by Brigido Stephen of 200000 shares of Celularity subject to Rule 16b-3 | ||
Lim Kok Thay over a month ago Disposition of 652981 shares by Lim Kok Thay of Celularity at 2.4898 subject to Rule 16b-3 | ||
Berman Richard J over two months ago Acquisition by Berman Richard J of 67416 shares of Celularity subject to Rule 16b-3 | ||
Diamandis Peter over two months ago Acquisition by Diamandis Peter of 84746 shares of Celularity at 2.225 subject to Rule 16b-3 | ||
Smith Robin L over three months ago Acquisition by Smith Robin L of 199921 shares of Celularity subject to Rule 16b-3 | ||
Berman Richard J over six months ago Insider Trading |
Celularity Notable Stakeholders
A Celularity stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Celularity often face trade-offs trying to please all of them. Celularity's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Celularity's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Stephen DPM | President Diseases | Profile | |
| John Haines | Corporate EVP | Profile | |
| MBA MD | Chief VP | Profile | |
| Kyle Esq | General VP | Profile | |
| Carlos Ramirez | SVP Relations | Profile | |
| Sharmila MD | Senior Safety | Profile | |
| CFA CFA | Chief Officer | Profile | |
| Tim Wilk | Senior Operations | Profile | |
| Ramji Krishnan | Chief Officer | Profile | |
| Bradley Glover | Ex COO | Profile | |
| CPA MS | Treasurer | Profile | |
| David CFA | Chief Officer | Profile | |
| Robert MD | CEO Founder | Profile | |
| Beth Steinbrenner | Ex HR | Profile | |
| Timothy Smith | Secretary | Profile | |
| Keary Esq | Gen EVP | Profile | |
| Anne Jones | Exec Officer | Profile |
About Celularity Management Performance
The success or failure of an entity such as Celularity often depends on how effective the management is. Celularity management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Celularity management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Celularity management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey. Celularity operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 225 people.
Please note, the imprecision that can be found in Celularity's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Celularity. Check Celularity's Beneish M Score to see the likelihood of Celularity's management manipulating its earnings.
Celularity Workforce Analysis
Traditionally, organizations such as Celularity use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Celularity within its industry.Celularity Manpower Efficiency
Return on Celularity Manpower
| Revenue Per Employee | 189.8K | |
| Revenue Per Executive | 1.3M | |
| Net Loss Per Employee | 1.6M | |
| Net Loss Per Executive | 11.5M |
Additional Tools for Celularity Stock Analysis
When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.